Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Next Previous
Trial Profile

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daraxonrasib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RASolute 303
  • Sponsors REVOLUTION Medicines

Most Recent Events

  • 24 Jun 2026 According to a Revolution Medicines media release, trial in progress poster will be presented at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1-4, 2026 in Munich, Germany.
  • 06 May 2026 According to a REVOLUTION Medicines media release, data from RMC-6236-001 and RMC-GI-102 trials will support the broad clinical impact of daraxonrasib and bolster the rationale for the ongoing RASolute 303 study.
  • 02 Apr 2026 According to Revolution Medicines media release, the company has begun treating patients in RASolute 303.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top